Radiotherapy (RT) for prostate cancer (PC) can cause erectile dysfunction (ED) by damaging neurovascular structures with oxidative stress. In this study, we evaluated the effects of resveratrol, an antioxidant, on post-RT ED. Fifty rats in five groups were evaluated; control (C), prostate-confined radiotherapy with short- and long-term vehicle or resveratrol treatment. Cavernosal tissues were obtained to analyze glutathione (GSH), nitric oxide (NO), cyclic guanosine monophosphate (cGMP), 8-hydroxy-2'-deoxy-guanosine (8-OHdG) levels and superoxide dismutase (SOD), caspase-3 activities, sirtuin-1, Foxo-3, nNOS, and eNOS protein expressions. Intracavernosal pressures (ICP) were measured for the long-term treatment group. In the RT + long-term vehicle treatment group, tissue GSH, NO, cGMP, and SOD activity were decreased while 8-OHdg levels and caspase-3 activities were increased. Radiotherapy caused a decrease in sirtuin-1, nNOS, and eNOS protein expressions. These parameters were reversed by resveratrol treatment. Foxo-3 protein expressions were unaltered in the RT + short-term vehicle treatment group and started to increase as a defense mechanism in the RT + long-term vehicle group; however, resveratrol treatment caused a significant increase in Foxo-3 expressions. Resveratrol preserved the metabolic pathways involved in erectile function and provided functional protection. Resveratrol can be used as a supplementary agent in patients undergoing radiotherapy to preserve erectile function.
ObjectivesTo investigate the possible protective effects of resveratrol against oxidative testicular damage due to scattered radiation during pelvic ionizing radiation exposure in rats.MethodsRats were divided into 5 groups; control, radiation, and radiation + resveratrol therapy in early and late periods. Under anesthesia, 20 Gy ionizing radiation was applied to prostatic region. Resveratrol was administered (10 mg/kg/day) orally before ionizing radiation exposure. Animals were decapitated at the end of 1st and 10th weeks. Biochemical markers of oxidative stress; caspase-3 and sirtuin-1 protein expressions; testosterone levels were evaluated, histological examinations were performed.ResultsSignificant increases in malondialdehyde, 8-hydroxy-deoxyguanosine levels, myeloperoxidase, and caspase-3 activities were observed after ionizing radiation exposure, also superoxide dismutase and glutathione activities were significantly decreased. Radiotherapy increased caspase-3 and decreased sirtuin-1 protein expressions. Resveratrol treatment significantly reversed these parameters and also reversed the decrease in testosterone levels back to control levels in late period.ConclusionResveratrol showed antioxidant and sirtuin-activating properties against oxidative damage caused by scattered radiation to testis and provided hormonal protection. These results suggest that resveratrol may be an alternative protective agent on testicular tissues against the effects of scattered pelvic radiation.
Results: Eighty patients were included in this study. The median age of the patients was 83 years (range: 80-94 years). Performance status of 62 patients was 0-1. Twenty-nine patients were treated with concurrent chemoradiotherapy, and 28 patients were treated with involved-field radiotherapy. The median follow-up period was 15.3 months. The 1-year and 3-year OS rates were 85.8% and 61.1%, respectively. In the univariate Cox's hazards model, clinical stage (hazard rate [HR]: 1.63, 95% confidence interval [95% CI]: 1.05 e 2.59, p Z 0.029) and albumin level (HR: 0.37, 95% CI: 0.16 e 0.88, p Z 0.025) were significant predictors for OS. However, there was no significant predictor in the multivariate Cox's hazards model. Conclusion: Clinical stage and blood albumin level were significant predictors in the univariate analysis. These predictors might help decisionmaking for patients aged 80 years or older who had esophageal cancer. However, further data and analysis are needed.
12-17 Gy) and the median depth was 0.9 cm (0.8-1.2 cm). The 6-MeV and 9 MeV electron were utilized in 28 (75.7%) and 9 (24.3%) patients, respectively. The median hospitalization after radiotherapy was 9 days. None of them had acute and late radiation-induced liver disease (RIL-D).Intrahepatic recurrence and extrahepatic recurrence were recorded in 14 patients (37.8%) and 3 patients (8.1%). There was no in-field failure. The 3-year overall survival (OS) and disease-free survival (DFS) were 84.8% and 45.5%, respectively. The results were preferable compared with historical data of narrow hepatectomy alone in our institution (3-year OS 74.5%, 3-year DFS 40.1%). Conclusion: A single dose of 15Gy IOERT is efficient and safe, with favorable local control and survival in LCHCC after narrow hepatectomy. Further evaluation based on larger cases and longer follow up time is warranted.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.